Viewing

Latest News



ESCRS 2026: Why retinal measurements can be wrong
0:56
ESCRS 2026: Why retinal measurements can be wrong
2 days ago
ESCRS 2026: What makes a good candidate for aceclidine drops?
0:39
ESCRS 2026: What makes a good candidate for aceclidine drops?
4 days ago
Intra-Operative OCT During Glaucoma Surgeries
1:03
Intra-Operative OCT During Glaucoma Surgeries
6 days ago
Building a low-level light therapy workflow
0:50
Building a low-level light therapy workflow
7 days ago
AI's growing role in ophthalmology screening and outcomes analysis
1:08
AI's growing role in ophthalmology screening and outcomes analysis
8 days ago
Dr. Radhika Rampat: AI in practice today
0:40
Dr. Radhika Rampat: AI in practice today
9 days ago
Piotr Wozniak, MD, discusses fast ocular surface stabilization with dry eye lubricating drop at EDES 2026
0:33
Fast ocular surface stabilization with dry eye lubricating drop: Piotr Wozniak, MD
a month ago
Ensuring cataract patients are happy
0:36
Redefining surgical success as "20/happy"
2 months ago
How ectoine's molecular shield protects the ocular surface
0:58
How ectoine's molecular shield protects the ocular surface
2 months ago
Managing cataract surgery patients
0:41
Counseling low myopes before cataract surgery: C. Ellis Wisely, MD, MBA
2 months ago

Digital Edition


Podcasts



All News

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.